Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellumen, a provider of cell-based drug discovery and discovery toxicology solutions, has launched a new pharmaceutical screening technology to help discover new drugs to treat Alzheimer's disease. This technology was jointly developed by Cellumen and the Alzheimer's Drug Discovery Foundation.
Subscribe to our email newsletter
Alzheimer’s Drug Discovery Foundation (ADDF) provided support for the development of novel tools for drug discovery applications, including cellular models of disease and biosensors that allow for sensitive detection of the interaction between two proteins involved in Alzheimer’s disease, CDK5 and p25.
Kate Johnston, chief scientific officer of Cellumen, said: “Cellumen is grateful for the support of the ADDF and for the opportunity to develop products and applications for important targets that have been difficult to screen with traditional drug discovery methodology.”